Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001

Journal of the National Cancer Institute

Volumn 94, Issue 24, 2002, Pages 1883-1888

  Baker, Sharyn D ^a   Verweij, Jaap ^b   Rowinsky, Eric K ^c   Donehower, Ross C ^a   Schellens, Jan H M ^b   Grochow, Louise B ^a   Sparreboom, Alex ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 5 ETHYNYLURACIL; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; 7 N [2 (4 NITROPHENYLDITHIO)ETHYL]MITOMYCIN C; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAPECITABINE; CARZELESIN; CILENGITIDE; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOCOSAHEXAENOIC ACID; FLUOROURACIL; IRINOTECAN; LEDOXANTRONE; LONAFARNIB; LURTOTECAN; NEMORUBICIN; PACLITAXEL; PEMETREXED; PLEVITREXED; TEMOZOLOMIDE; TIPIFARNIB; TOPOTECAN; TROXACITABINE; UNINDEXED DRUG;

ADULT; BODY SURFACE; CLINICAL STUDY; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG EXPOSURE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

EID: 0037132703     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.24.1883     Document Type: Review

References (81)

1. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590-611.
2. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19: 171-7.
3. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16:2297-8.
4. de Jongh FE, Verweij L Loos WJ, de Wit R, de Jonge MJ, Planting AS, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-9.
5. Mathijssen RH Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-7.
6. Danesi R, De Braud F, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 2001;22:420-6.
7. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.
8. Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 2002;38:639-44.
9. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001;1: 99-108.
10. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990;82: 323-5.
11. de Jonge MJ, Punt CJ, Gelderblom AH, Loos WJ, van Beurden V, Planting AS, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 1999;17:2219-26.
12. de Jonge MJ, Verweij J, Loos WJ, Dallaire BK, Sparreboom A. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clin Pharmacol Ther 1999;65:491-9.
13. Gelderblom H, Salazar R, Verweij J, O'Neill V, Sparreboom A, Principe P, et al. Oral bioavailability of BN80915 in adult patients with solid tumors. Proc Am Assoc Cancer Res 2001;42:2895.
14. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000;83:22-9.
15. Gilbert J, Dees EC, Baker SD, Summerson L, Carducci MA, Izumi T, et al. A phase I study of CS-682, an oral antimetabolite, in patients with refractory solid tumors. Clin Cancer Res 2000;6:4554s.
16. Brindley CJ, Morrison R, Gordon RJ, Devlin AJ, van der Gaast A, Verweij L, et al. Clinical pharmacokinetics of 2′-deoxy-2′-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent. Clin Pharmacokinet 2000;38:475-91.
17. Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000;18:915-26.
18. Eskens FA, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J, et al. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. Clin Cancer Res 2000;6:431-3.
19. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, et al. Phase I and pharmacological study of the oral matrix metallo-proteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22.
20. Gilbert L Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-300.
21. Hoekstra R, Dumez H, Eskens F, Sizer K, Cohen P, Ravera C, et al. A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer. Clin Cancer Res 2001;7: 3771s.
22. Verweij J, Kehrer DF, Planting AS, de Jonge MJ, Klaren A, de Hens G, et al. Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R 115777. Proc ASCO 200 1;20:81a.
23. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001;19:1167-75.
24. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;17:2604-13.
25. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-71.
26. Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 1998;34:1030-5.
27. Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998;4:1153-8.
28. Creemers GL Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15:1087-93.
29. de Jonge MJ, Loos WJ, Gelderblom H, Planting AS, van der Burg ME, Sparreboom A, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 2000;18:2104-15.
30. Gelderblom AJ, Loos WL de Jonge MJ, Sparreboom A, Planting AS, van der Burg ME, et al. Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin. Ann Oncol 2000;11:1205-7.
31. Gelderblom H, Sparreboom A, de Jonge MJ, Loos WJ, Wilms E, Mantel MA, et al. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. Br J Cancer 2001;85:1124-9.
32. Loos WL Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000;6: 2685-9.
33. de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van de Schraaf J, et al. Phase I and pharmacologic study of ZD 9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002;20: 1923-31.
34. Sparreboom A, de Jonge MJ, Punt CJ, Nooter K, Loos WJ, Porro MG, et al. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clin Cancer Res 1998;4: 1915-9.
35. Planting AS, Schellens JH, van der Burg ME, de Boer-Dennert M, Winograd B, Stoter G, et al. Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. Anticancer Drugs 1999;10: 821-7.
36. van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, et al. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol 1998; 41:377-84.
37. Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res 2000;6: 3885-94.
38. Louwerens M, Smorenburg CH, Sparreboom A, Loos WJ, Verweij J, de Wit R. Phase I and pharmacokinetic study of the combination of docetaxel and methotrexate in patients with solid tumors. Eur J Cancer 2002;38: 497-504.
39. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000;6:1365-71.
40. van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002;38:1090-9.
41. Kennedy MJ, Elza K, Donehower R, Hoker B, Chen TL, Rowinsky EK. Phase I and pharmacologic (PK) study of docetaxel and doxorubicin in patients (pts) with solid tumors: dose limiting toxicity at the first dose level. Proc ASCO 1997; 16:240a.
42. Wolff AC, Krishnamurthi S, Sparano JA, Armstrong DK, Davidson NE, Fetting JH, et al. A pharmacokinetic (PK) and pharmacodynamic study of doxorubicin and docetaxel combinations plus marimastat (AT/M) in metastatic breast cancer (MBC). Proc ASCO 2001;20:98a.
43. 5 integrins: Mature results of a phase I and pharmacological study. Clin Cancer Res 2000;6:4524s.
44. Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 1994;86:906-12.
45. Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, et al. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anticancer Drugs 2001;12:583-90.
46. de Jonge Mi, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose- escalating study of irinotecan and cisplatin. J Clin Oncol 2000;18:195-203.
47. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7: 1136-41.
48. Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, et al. Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drugs 2002;20:83-93.
49. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44: 372-80.
50. Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, et al. Phase I and pharmacologic study of liposomal lurtotecan (NX 211): urinary excretion predicts hematologic toxicity. J Clin Oncol 2002;20: 1222-31.
51. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, et al. Comparative pharmacokinetics of unbound paclitaxel during I- and 3-hour infusions. J Clin Oncol 2002;20:574-81.
52. van der Gaast A, Polee M, Eskens F, Hoekstra R, van der Burg M, Sparreboom A. Phase I and pharmacokinetic study with weekly paclitaxel and increasing doses of weekly carboplatin in patients with esophageal or gastric junction cancer. Proc ASCO 2002;21:155a.
53. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
54. Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, et al. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase I and pharmacokinetic study. Br J Cancer 2000;82:767-71.
55. de Jonge MJ, Wortelboer M, van der Gaast A, Morant R, Colajori E, Valota O, et al. PNU-159548, a novel alkycycline: phase I and pharmacokinetic studies in patients with advanced solid tumors. Proc ASCO 2000;19: 201a.
56. de Jonge MJ, ten Tije AJ, van der Gaast A, Fiorentini F, Fowst C, Tursi J, et al. Phase I and pharmacokinetic study on PNU-166196, a novel minor groove binder potentiated by glutathione (GSH) and GSH-transferase, administered intravenously once every 3 weeks to patients with advanced cancer. Clin Cancer Res 2001;7:3797s.
57. Eskens FA, Greim GA, van Zuylen C, Wolff I, Denis LJ, Planting AS, et al. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Clin Cancer Res 2000;6: 1736-43.
58. van Zuylen L, Eskens FA, Bridgewater J, Sparreboom A, Sklenar I, Planting AS, et al. The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer: results of a phase I and pharmacologic study. Proc ASCO 2000;19: 193a.
59. Donehower R, Elze-Brown K, O'Reilly S, Isreal B, Grochow L. A phase I dose escalation, safety, tolerability, and pharmacokinetic study of TAS-103 in patients with refractory solid tumors. Proc ASCO 1998;17:209a.
60. Wolff AC, Baker SD, Bowling MK, Carducci MA, Bradley MO, Anthony FH, et al. Phase I study of taxoprexin DHA-paclitaxel (TXP), a novel taxane with unique preclinical activity, toxicity profile, and pharmacology. Clin Cancer Res 2000;6:4580s.
61. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
62. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-84.
63. Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:1224-35.
64. Gelderblom H, Loos WJ, Sparreboom A, van Zomeren DM, de Jonge MJ, Verweij J. Influence of hydration schedule on cisplatin pharmacokinetics in the combination cisplatin followed by topotecan. Proc Am Assoc Cancer Res 2002;43:123.
65. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-73.
66. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88: 817-24.
67. de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, et al. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2002;20:96-109.
68. Dees EC, O'Reilly S, Figg WD, Elza-Brown K, Aylesworth C, Carducci M, et al. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor. Proc ASCO 2000;19: 205a.
69. Gibaldi M, Perrier D. Pharmacokinetics. New York (NY): Marcel Dekker, Inc.; 1982.
70. Takimoto CH, Baker SD, Sweeney CJ, Goetz A, Felton S, Hammond L, et al. Phase I and pharmacokinetic study of pemetrexed disodium (LY231514, MTA, Alimat) in patients (pts) with impaired renal function. Proc ASCO 2001;20:93a.
71. Smith HW. The kidney, structure and function in health and disease. New York (NY): Oxford University Press; 1951.
72. Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular filtration rate. Cancer Chernother Pharmacol 2000;46:523-6.
73. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Ear J Cancer 2002;38:11-6.
74. Baker RJ, Kozoli DD, Meyer KA. The use of surface area for establishing normal blood volume. Surg Gynecol Obstet 1957;104: 183-9.
75. Wolner E, Domanig E Jr, Elkadi A, Helmer F, Romer P. On a simple relation between blood volume and body surface area. Z Kreislaufforsch 1968;57:79-84.
76. Baker SD, Wolff AC, Zabelina Y, McIntyre G, Swindell CS, van Zomeren DM, et al. Disposition of Taxoprexin, DHA-paclitaxel (DHA-PAC), a novel taxane, in blood: in vitro and clinical pharmacokinetic (PK) studies. Clin Cancer Res 2001:7:3677s.
77. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha 1 -acid glycoprotein. Cancer Res 1998;58:3248-53.
78. Sparreboom A, Nooter K, Loos WJ, Verweij J. The (ir)relevance of plasma protein binding of anticancer drugs. Neth J Med 2001;59: 196-207.
79. Sparreboo A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblo H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
80. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998;4:1937-42.
81. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.